Needham & Company LLC Reiterates Buy Rating for Quantinuum (NASDAQ:QNT)

Quantinuum (NASDAQ:QNT)‘s stock had its “buy” rating reissued by equities research analysts at Needham & Company LLC in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $100.00 price objective on the stock. Needham & Company LLC’s price objective suggests a potential upside of 78.38% from the company’s current price.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen cut Quantinuum from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. UBS Group began coverage on Quantinuum in a research report on Monday, June 29th. They issued a “buy” rating and a $93.00 price objective on the stock. Craig Hallum began coverage on Quantinuum in a research note on Monday, June 29th. They issued a “buy” rating and a $100.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of Quantinuum in a report on Monday, June 29th. They set an “overweight” rating and a $90.00 price objective for the company. Finally, TD Cowen initiated coverage on shares of Quantinuum in a report on Monday, June 29th. They issued a “buy” rating on the stock. Twelve equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $98.33.

Quantinuum Stock Down 0.9%

Shares of NASDAQ QNT opened at $56.06 on Wednesday. The firm’s 50 day simple moving average is $62.71. Quantinuum has a fifty-two week low of $47.06 and a fifty-two week high of $86.79.

Quantinuum (NASDAQ:QNT) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The company had revenue of $8.00 million during the quarter. On average, sell-side analysts anticipate that Quantinuum will post -1.61 EPS for the current year.

Insider Buying and Selling at Quantinuum

In related news, Director Kenneth D. Denman bought 14,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The stock was bought at an average cost of $60.00 per share, with a total value of $840,000.00. Following the completion of the purchase, the director owned 19,833 shares of the company’s stock, valued at approximately $1,189,980. The trade was a 240.01% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Manish H. Bhatia bought 20,000 shares of Quantinuum stock in a transaction dated Friday, June 5th. The stock was purchased at an average cost of $60.00 per share, for a total transaction of $1,200,000.00. Following the completion of the acquisition, the director directly owned 25,833 shares of the company’s stock, valued at approximately $1,549,980. The trade was a 342.88% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders bought 411,032 shares of company stock worth $24,661,920.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Quantinuum stock. Lisanti Capital Growth LLC acquired a new position in Quantinuum Inc. (NASDAQ:QNT) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,005 shares of the company’s stock, valued at approximately $409,000.

More Quantinuum News

Here are the key news stories impacting Quantinuum this week:

• Positive Sentiment: Quantinuum reported second-quarter revenue of $8 million, a 279% year-over-year increase, and raised its fiscal 2026 revenue outlook to $28 million-$32 million versus the $26.6 million analyst consensus. Quantinuum Reports Second Quarter 2026 Results
• Positive Sentiment: Quantinuum announced a multiyear partnership with Oracle (NYSE: ORCL) to deploy its 98-qubit Helios system in a U.S.-based Oracle Cloud Infrastructure AI data center. Customers will be able to access hybrid quantum-AI and high-performance computing capabilities through Oracle Cloud without owning specialized quantum hardware, potentially accelerating commercial adoption. Oracle, Quantinuum partner to bring quantum computing to cloud
• Positive Sentiment: The company said Helios demonstrated near five-nines logical fidelity, reinforcing Quantinuum’s positioning in fault-tolerant quantum computing. The Oracle deployment could provide an important bridge from technical milestones to applications such as drug discovery, materials science, financial modeling and optimization. Quantinuum Puts a 98-Qubit Helios Machine Inside Oracle’s AI Data Centers
• Negative Sentiment: Quantinuum reported an adjusted loss of $0.28 per share, slightly worse than the $0.26 consensus estimate. The earnings shortfall and the company’s still-small revenue base appear to have outweighed the favorable outlook and strategic partnership, helping explain why the stock finished lower. Quantinuum Reports Second Quarter 2026 Results

Quantinuum Company Profile

Quantinuum is a quantum computing company focused on developing hardware and software for commercial and scientific applications. The company provides access to its quantum systems, along with software tools and services designed to help customers explore use cases in areas such as optimization, materials science, chemistry, cybersecurity, and machine learning.

The company was formed through the combination of Honeywell Quantum Solutions and Cambridge Quantum in 2021. Quantinuum operates internationally and serves a range of customers across enterprise, government, and research markets.